Home › Trial NCT06549816
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- Trial IDNCT06549816
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorSeagen, a wholly owned subsidiary of Pfizer
- Enrollment6
- Start date2024-08-21
- ConditionsCarcinoma, Non-Small Cell Lung · Squamous Cell Carcinoma of Head and Neck · Esophageal Squamous Cell Carcinoma · Gastric Adenocarcinoma · Esophageal Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.